Bavarian Nordic A/S announced positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of its virus-like particle -based chikungunya virus vaccine candidate, CHIKV VLP in adults and adolescents aged 12 to 64 years of age.
